Sab Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sab Biotherapeutics Inc 's ROA in the second quarter of 2026?
Sab Biotherapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -6.06%.

However, within the Healthcare sector 267 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 541 to 2587.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	690.62 %	551.81 %	291.01 %	242.02 %	-51.32 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	0	13	19	-37
Return On Assets (TTM)	-6.06 %	-0.25 %	12.49 %	25.29 %	-89.16 %
SABS's Total Ranking	# 2587	# 541	# 174	# 4398	# 4347
Total Assets (TTM) in million	238	248	173	184	30
Seq. Total Assets Change	-4.13 %	43.78 %	-6.08 %	510.7 %	-20.96 %
Seq. Net Income Change	-	-	-	-	-

SABS's 5 Years Annual ROA >> Back to SABS Management Effectiveness >> Compare SABS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 28
Sector	# 268
Overall	# 3015

Return On Assets Statistics
High	Average	Low
25.33 %	-37.57 %	-89.16 %
(Sep 30 2025)		(Jun 30 2025)

Financial Statements
Sab Biotherapeutics Inc 's Assets	$ 238 million	SABS's Balance sheet
Sab Biotherapeutics Inc 's Income	$ -22 million	Quarterly SABS's Income Statement
SABS's Income by Division		See SABS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	397.12 %	-47.35 %	66.72 %	-37.95 %	58.21 %
Total Assets in million	220	44	84	50	81
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	13	-34	-42	-19	-17
Annual Return On Assets	6.04 %	-77.17 %	-50.27 %	-37.22 %	-21.13 %

SABS's 5 Years Annual ROA >> Back to SABS Management Effectiveness >> Compare SABS ROA to its Competitors

Comment on SABS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.04 % compared to prior year, due to annual net income growth of % to $13.27 million, while value of Sab Biotherapeutics Inc 's overall assets grew just by 397.12 % to $219.70 million, compared to $219.70 a year before.

More Return On Assets Ratios
SABS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SABS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SABS's Competitors
Subscribers only: Roa for Sab Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SABS's Customers

You may also want to know
SABS's Roi	SABS's Inventory Turnover Ratio	SABS's Growth Rates	SABS's Dividend Comparisons
	SABS's Profitability Ratios	SABS's Asset Turnover Ratio	SABS's Dividend Growth
SABS's Roe	SABS's Valuation Ratios	SABS's Financial Strength Ratios	SABS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.